Why early, sustained joint support belongs at the centre of high-performance horse management in Canada
For the Canadian high-performance horse — the dressage, jumping and eventing athletes campaigning toward national titles, FEI competition, team selections or horses used for developing young athletes — osteoarthritis (OA) remains one of the most significant causes of reduced performance and premature retirement. While long associated with the older horse, the underlying process — chronic, low-grade inflammation that gradually compromises cartilage, synovial fluid and the joint capsule — frequently begins much earlier in life than clinical signs would suggest. By the time a subtle loss of cadence, a shortened stride or a drop in scores becomes apparent at the top level, the joint has typically been adapting for some time.
Osteoarthritis is progressive and, while manageable, currently not curable. That reality places considerable importance on early intervention. The risk factors are well established and largely unavoidable in horses competing at the elite level: the cumulative load of training and competition, conformational predispositions, competition surfaces, the demands of frequent travel, and the practice of starting horses too young in some disciplines. For the high-performance program, the question is no longer whether to support joint health, but when.
From a program perspective, the strongest case for prevention is straightforward. Joint function will most likely begin to decline well before clinical signs appear. The window in which intervention can support, rather than respond to, structural change is therefore narrower than it often seems at the point of presentation. For programs built around long competitive campaigns and the protection of equine athletes of considerable value, proactive daily support helps maintain career longevity. With such measures incorporated into a horse’s daily management, many horses can continue to perform soundly into their late teens and beyond — an outcome that aligns both welfare considerations and the practical realities of a high-performance career.
4CYTE™ Epiitalis® Forte is an advanced daily oral veterinary health supplement, formulated to support joint health and function in horses and suitable for long-term use. It is powered by Epiitalis®, a globally patented plant seed oil extract that is the world-exclusive active ingredient in the 4CYTE™ range. Epiitalis® is patented for its ability to help maintain healthy cartilage development. The unique fatty acid profile of the extract is understood to play a signalling role to chondrocytes — the cells responsible for cartilage maintenance — supporting the cartilage matrix, helping maintain a normal inflammatory response, and supporting healthy cartilage and joint function. For competition horses, it is also non-swabbable, an important practical consideration under clean-sport rules.
The evidence base is product-specific rather than ingredient-only, which is uncommon in the joint supplement category. Research has been conducted here in Canada at the University of Guelph, alongside peer-reviewed work at Colorado State University — including studies involving Professor Wayne McIlwraith — which examined Epiitalis® in horses following joint injury. Over a 70-day period, horses receiving Epiitalis® showed significant reductions in total radiographic scores — an indicator of OA progression — compared with placebo, alongside a significant reduction in inflammation within the synovial fluid.
Further studies have been conducted at the University of Melbourne in Australia.
In clinical use, 4CYTE™ Epiitalis® Forte is suitable for long-term use and is suitable for use from 6 months of age. It is suitable for use alongside other treatments a veterinarian may prescribe for joint health management — a practical consideration for elite horses, where multimodal approaches are common. The supplement is administered as a once-daily oral dose, is highly palatable, easily digestible and readily absorbed, which supports the consistent daily administration that long-term joint support requires.
4CYTE™ Epiitalis® Forte is surgeon- and veterinarian-endorsed, backed by peer-reviewed and published studies, and represents an evidence-based addition to a comprehensive approach to equine joint health. As the conversation in performance practice continues to shift from the management of established disease toward earlier, structured support, the case for incorporating evidence-based joint health interventions earlier in a horse’s working life becomes increasingly difficult to set aside — particularly for Canada’s elite horses and the riders, owners and veterinary teams responsible for their welfare and career longevity.
To learn more about 4CYTE™ Epiitalis® Forte and the research behind Epiitalis®, visit ca.4cyte.global.